Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.34 USD | -0.83% | -15.50% | +63.99% |
10/05 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
09/05 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+63.99% | 163.26Cr | |
+29.77% | 4.82TCr | |
-0.63% | 4.17TCr | |
+43.51% | 4.1TCr | |
-5.31% | 2.88TCr | |
+10.60% | 2.56TCr | |
-21.63% | 1.9TCr | |
+8.04% | 1.29TCr | |
+27.50% | 1.2TCr | |
-3.20% | 1.18TCr |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Wedbush Raises Edgewise Therapeutics' PT to $26 From $23, Continues to See 2024 as Critical Year; Keeps Outperform Rating